Objective To investigate whether transforming growth factor-β1 (TGF-β1) could induce the expression of twist protein in the human kidney tubular epithelial cells (HKCs).Methods Human proximal HKCs were cultured in vitro and divided into three groups as follows:control group,TGF-β1group (10 ng/ml),and TGF-β1 + wortmannin group (10 ng/ml,10nmol/l,respectively).After cultured for 48 hours,cell immunofluorescene was used to observe the expression of E-cadherin and alpha-smooth muscle actin (α-SMA).Meanwhile,Western blotting was used to detect the protein expression of E-cadherin,α-SMA,and twist.Results Compared to control group,the protein expressions of E-cadherin were significantly decreased in T group (3.54 ± 0.17 vs 16.06 ± 0.50,P =0.001),whereas the protein expressions of α-SMA and twist were significantly increased in T group (α-SMA:14.78 ± 0.48 vs 3.75 ± 0.50,P=0.001 ;twist:14.24 ±0.14 vs 3.06 ±0.15,P =0.001).Compared to T group,a significant increase of the E-cadherin protein expression was detected in TGF-β1 + wortmannin group (15.88 ± 0.36,3.46 ±0.19,P =0.001),whereas,the protein expressions of α-SMA and twist were significantly decreased in TGF-β1 + wortmannin group (α-SMA:3.50 ±0.39 vs 15.0 ±0.24,P =0.001 ;twist:3.09 ±0.1 vs 14.04± 0.16,P =0.001).Cell imunofluorescence showed that the expressions of E-cadherin and α-SMA were consistent with the results of Western blotting.Conclusions TGF-β1 can induce the expression of twist protein in HKCs through Akt pathways.

Objective To study the effects of motor imagery therapy on functional performance of upper ex- tremity in stroke patients.Methods Sixty cases of stroke were divided into a treatment group(n=30) and a con- trol group(n=30).The control group was treated with routine rehabilitation training,while the treatment group was treated with motor imagery therapy in addition to the routine rehabilitation training.The Fugl-Meyer Assessment (FMA),upper extremity function test(UEFT)and simple test for evaluating hand function(STEF)were used to as- sess the upper extremity function before and after six months of treatment.Results After treatment,patients in both groups scored significantly better with the FMA scales,UEFT scales and STEF scales when compared to their scores obtained before the treatment(P

Objective To inquire clinical effects of hysteroscopic electroresection in the treatment of submucous hysteromyoma. Methods A retrospective analysis regarding curative effects of hysteroscopic electroresection in 72 cases of submucous hysteromyoma was carried out. Results The resected myoma was 1.5~7 cm in diameter, and the number of resected myoma was 1~3. The operation time was 10~90 min (mean, 30 min). The operation was accomplished on one session in all the 72 cases. No uterine perforation, bleeding and bowel injuries took place. Postoperative follow-up for 4~20 months in the 72 cases reported a satisfaction rate of 97 2% (70/72). Out of 6 patients who had pregnancy desire, 2 were pregnant with child and 1 of them had a delivery. Conclusions Hysteroscopic electroresection in the treatment of submucous hysteromyoma is safe and effective. It can markedly improve the menstruation and elevate the pregnancy rate.

Heart failure is a syndrom of heart disease with high morbidity and mortality .There are more and more evidence indicating immune activation developing important role in the occurrence and development of heart failure . Interleukin (IL)‐35 ,known as a negative regulatory factor of one of the members of IL‐12 family ,participates pathogenetic process of heart failure .The present article made a review for influence of IL‐35 on heart failure .

Pyruvate dehydrogenase kinases(PDKs 1-4) can regulate the activity of mitochondrial pyruvate dehydrogenase complex(PDC) to catalyse the oxidative decarboxylation of pyruvate,and then to link glycolysis to the tricarboxylic acid cycle and ATP production.In this review,we summarize up-to-date information of mechanisms regulating PDKs and the function of PDKs inhibitors in lowering blood glucose level,alleviate damage during heart ischemia and also triggering apoptosis in cancer cells.PDKs will be a possible pharmacological targets in diabetes,heart ischemia and cancer therapy.

AIM:To observe the clinical effects of Huangkui Capsule (Abelmoschus manihot (Linn)Medic.)on the treatment of IgA nephropathy of damp-heat syndrome.METHODS: Sixty-four patients were assigned randomly into two groups: treatment group in which 32 cases were treated with Huangkui Capsule,and control group,in which 32 cases were treated with fosinopril.The therapeutic course for both groups was 12 weeks.The indexes of efficacy ,including damp-heat syndrome scores,24 h urinary protein,serum creatinine,urea nitrogen and the indexes of safety,including liver function,electrolyte and occurrence of adverse events were observed.RESULTS :There was no significant statistical difference between the two groups in aspects of baseline clinical figures,after 12 weeks of treatment,the content of 24h urinary protein significantly decreased by (0.49±0.78 )g/24 h and (0.4±0.76 ) g/24 h respectively in the two groups,showing significant difference in comparing with baseline,but insignificant difference between the two groups ( P ＞ 0.05 ),the scores of damp-heat syndrome in the two groups decreased by (0.88±1.43 ) scores and (1.94±1.63 ) scores respectively with significant difference as compared with baseline (P ＜0.05 ),and in comparison between groups(P ＜0.05 ).The total effective rate of 24 h urinary protein was 53.1% in the treatment group and 65.6% in the control group (P ＞ 0.05 ),The total effective rate of dampheat syndrome scores was 84.4% in the treatment group and 50% in the control group ( P ＞ 0.05 ).No significant change in levels of serum creatinine,urea nitrogen in the two groups was found (P ＞0.05 ).No severe adverse event occurred during the treatment,and the occurrence in the two groups was similar.CONCLUSION: Huangkui Capsule can effectively decrease the proteinuria just like fosinopril and improve clinical syndrome of patients of IgA nephropathy with damp-heat syndrome type,and shows no serious adverse reaction.

0.05).No severe adverse event occurred during the treatment,and the occurrence in the two groups was similar.CONCLUSION:Huangkui Capsule can effectively decrease the proteinuria just like fosinopril and improve clinical syndrome of patients of IgA nephropathy with damp-heat syndrome type,and shows no serious adverse reaction.

Overlapping PCR technology was employed to splice IFN?and HSA genes in vitro. The spliced gene was inserted into Pichia pastoris secretory vector pPIC9K. The IFN?-HSA gene was designed for secretory expression under the control of promoter AOX1 and Mat a signal peptide in pPIC9K. The recombinant plasmid pPIC9K/IFN?-HSA was linearized by restriction enzyme SalI and transformed into Pichia pastoris KM71 by electroporation. The recombinant strains identified by G418 selection and confirmed by PCR analysis were induced by methanol to express fusion protein IFNp-HSA. SDS-PAGE and Western blot analysis of the fusion protein showed that the expressed fusion protein IFNp-HSA with an apparent 90kDa molecular weight had the antigenicity of HSA. The specific activity of culture supernatant was about 640IU/ml assayed by the standard amiviral activity test on WISH cells challenged with VSV virus.

Angiotensin II ; pharmacology ; Cells, Cultured ; Focal Adhesion Protein-Tyrosine Kinases ; metabolism ; Humans ; Myocytes, Smooth Muscle ; cytology ; Pulmonary Artery ; cytology

Antineoplastic Agents ; administration & dosage ; therapeutic use ; Cladribine ; administration & dosage ; therapeutic use ; Humans ; Leukemia, Hairy Cell ; drug therapy ; Male ; Middle Aged